Identification of potential COVID-19 Mpro inhibitors through covalent drug docking, molecular dynamics simulation, and MMGBSA calculation

通过共价药物对接、分子动力学模拟和MMGBSA计算鉴定潜在的COVID-19 Mpro抑制剂

阅读:1

Abstract

The viral main protease is a critical drug target due to its role in the SARS-CoV-2 life cycle. In this study, we evaluated 2,000 potential Mpro inhibitors recommended by the FragRep server, with a focus on interactions with the CYS145 residue. Six top candidates were selected for each of the 7JKV and 7TDU Mpro structures, and covalent molecular docking was performed using SeeSAR. We docked twelve ligands to various Mpro sites and performed 100 ns molecular dynamics (MD) simulations on the highest-scoring ligands: lig-14-23, lig-6-32, lig-2-3, lig-0101, lig-7612, lig-811, and lig-837. MD analysis, including Root Mean Square Deviation (RMSD), Radius of Gyration (Rg), Solvent Accessible Surface Area (SASA), and Root Mean Square Fluctuation (RMSF), confirmed the stability of the covalent complexes. Non-covalent ligands, which exhibited higher toxicity profiles, were excluded from the molecular dynamics analysis. The results indicate that lig-7612 and lig-837 form stable interactions with Mpro, suggesting their potential as drug candidates. These inhibitors exhibit pharmacological properties that could influence drug interactions and metabolism in vivo. Further safety and pharmacokinetic assessments are required for therapeutic development.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。